|
IQVIA™ Real-World Insights Bibliography
|
Assessment of potential transthyretin amyloid cardiomyopathy cases in the Brazilian public health system using a machine learning model |
| Author(s):
Isabella Zuppo Laper (1), Cecilia Camacho-Hubner (2), Rafaela Vansan Ferreira (1), Claudenice Leite Bertoli de Souza (2), Marcus Vinícius Simões (3), Fabio Fernandes (4), Edileide de Barros Correia (5), Ariane de Jesus Lopes de Abreu (1), Guilherme Silva Julian (2) |
| Affiliations(s): 1: IQVIA Brazil; 2: Pfizer Brazil; 3: USP School of Medicine in Ribeirão Preto; 4: HC-FMU-SP; 5: Instituto Dante Pazzanese de Cardiologia |
Publication(s): PLoS One. 2024; 19(2): e0278738.
|
| Document Type(s): Article, |
| Countries: Brazil, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease,
2022 |
|
L:
A: |
English
|
|
 |
| |
| |
| Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Portugal |
| Author(s): Nuno Marques 1, Laetitia Gerlier 2, Mafalda Ramos 3, Helder Pereira 4, Sérgia Rocha 5, Ana Catarina Fonseca 6, Ana André 7, Ricardo Melo 8, Eduard Sidelnikov 9 |
| Affiliations(s): 1Department of Cardiology, Centro Hospitalar e Universitário do Algarve, Faro, Portugal.
2IQVIA, Zaventem, Belgium.
3IQVIA, Zaventem, Belgium. Electronic address: mafalda.ramos@iqvia.com.
4Department of Cardiology, Hospital Garcia de Orta, Almada, Portugal.
5Department of Cardiology, Hospital de Braga, Braga, Portugal.
6Department of Neurology, Hospital de Santa Maria, Universidade de Lisboa, Lisboa, Portugal.
7Department of Neurology, Centro Hospitalar e Universitário do Algarve, Faro, Portugal.
8Amgen SA, Portugal.
9Amgen (Europe) GmbH, Rotkreuz, Switzerland. |
Publication(s): PMID: 33581948 DOI: 10.1016/j.repc.2020.05.019
IQVIA HEOR Zaventem Brussels
Revista Portuguesa de Cardiologia Volume 40, Issue 2, February 2021, Pages 109-115.
|
| Document Type(s): Article, |
| Countries: Portugal, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Health economics,
2021 |
|
L:
A: |
English
Burden of illness, Clinical setting: Primary care, Prospective study, |
|
|
| |
| |
| Characterisation of Pulmonary Arterial Hypertension (PAH) Patients Initiating a New PAH Specific Therapy in the Context of Age: Insights from EXPOSURE |
| Author(s): P. Escribano (1), S. Gaine (2), P. Biedermann (3), A. Muller (3), M. Valge (4), T. Lange (5), S. Söderberg (6) |
| Affiliations(s): 1 Pulmonary Hypertension Unit, Cardiology Department, CIBERCV, Hospital 12 de Octubre, Madrid, Spain
2 National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland
3 Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
4 StatFinn Estonia OÜ, Tartu, Estonia (now IQVIA)
5 University Medical Center Regensburg, Regensburg, Germany
6 Department of Public Health and Clinical Medicine, Cardiology and Heart Centre, Umeå University, Umeå, Sweden |
Publication(s): JO - The Journal of Heart and Lung Transplantation
VL - 40
IS - 4, Supplement
SP - S109
PY - 2021
DA - 2021/04/01/
SN - 1053-2498
|
| Document Type(s): Abstract, |
| Countries: Canada, Europe, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease,
2021 |
|
L:
A: |
English
Epidemiological study, Observational study, |
|
|
| |
| |
| Effectiveness and safety of empagliflozin in routine care in Europe and East Asia: results from
the empagliflozin comparative effectiveness and safety (EMPRISE) study
|
| Author(s): A. Karasik1
, S. Lanzinger2
, E. Chia-Hui Tan3
, D. Yabe4
, D. Jung Kim5
, W. H-H Sheu6
, C. MelzerCohen1
, R.W. Holl2
, K. Ha5
, T. Nyström7
, L. Niskanen8
, M. Linnemann Jensen9
, M.H. Kyaw10, J.
Núñez11, EMPRISE EU and East Asia Study Group; |
| Affiliations(s): Maccabi Research & Innovation Center, Tel Aviv University, Tel Aviv, Israel, 2
Inst. for
Epidemiology & Medical Biometry, Uni. of Ulm, Ulm, Germany, 3National Research Inst. of Chinese
Medicine, Taipei, Taiwan, 4Dept. of Diabetes and Endocrinology, Gifu University Graduate School of
Medicine, Gifu, Japan, 5Dept. of Endocrinology & Metabolism, Ajou Uni. School of Medicine,
Suwon, Republic of Korea, 6Taipei Veterans General Hospital, Taipei, Taiwan, 7Dept. of Clinical
Science & Education, Södersjukhuset, Karolinska Institutet, Solna, Sweden, 8Department of Medicine,
Päijät-Häme Central Hospital, Lahti, Finland, 9
IQVIA, Copenhagen, Denmark, 10Boehringer
Ingelheim Pharmaceutical Inc., Ridgefield, USA, 11Dept. of Cardiology, Hospital Clínico
Universitario de Valencia, Valencia, Spain |
Publication(s):
https://doi.org/10.2337/DB21-127-LB
Virtual EASD 2021, 57 Annual Meeting, 27 September - 10 October 2021
|
| Document Type(s): Abstract, |
| Countries: Finland, Germany, Israel, Japan, South Korea, Spain, Sweden, Taiwan, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes,
2021 |
|
L:
A: |
English
Database Study, Methodology, Population Based Study, |
|
|
| |
| |
| Cardiovascular Effectiveness of Empagliflozin Compared to DPP-4i in Routine Care in East Asia: Results from the EMPRISE study |
| Author(s): Dae Jung Kim, Wayne H.-H. Sheu, Wook-Jin Chung, Daisuke Yabe, Kyoung Hwa Ha, Elise Chia-Hui Tan, Yusuke Taneda, Vanessa Lei, Laura Saarelainen, Anouk Deruaz-Luyet, Moe H. Kyaw, Yutaka Seino, EMPRISE East Asia Study Group, Boehringer Ingelheim International GmbH, Ingelheim, Germany, StatFinn - EPID Research an IQVIA Company, Espoo, Finland |
| Affiliations(s): 1 Ajou University, Suwon, South Korea; 2 Taichung Veterans General Hospital, Taichung, Taiwan; 3 Gachon University Gil Medical Center, Incheon, South Korea; 4 Kansai Electric Power Medical Research Institute, Kobe, Japan; 5 Gifu University Graduate School of Medicine, Gifu, Japan; 6 National Research Institute of Chinese Medicine, Taipei, Taiwan; 7 Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan; 8 Boehringer Ingelheim Taiwan Ltd., Taipei, Taiwan; 9 IQVIA, Espoo, Finland; 10 Boehringer Ingelheim International GmbH, Ingelheim, Germany; 11 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; 12 Kansai Electric Power Hospital, Osaka, Japan |
Publication(s): J Am Coll Cardiol. 2021 May, 77 (18_Supplement_1) 542.
https://doi.org/10.1016/S0735-1097(21)01901-X
|
| Document Type(s): Abstract, Presentation, |
| Countries: Japan, South Korea, Taiwan, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes,
2021 |
|
L:
A: |
English
Database Study, Methodology, Observational study, |
|
|
| |
| |
| Empagliflozin use versus dipeptidyl peptidase 4 inhibitors reduces risk ofcardiovascular and renal disease among type 2 diabetes patients in routinecare in europe and israel: EMPRISE study results |
| Author(s): T Nystroem1;AKarasik2; J Nunez3; S Lanzinger4; C Melzer-Cohen2; R W Holl4;P Casajust5; E Toresson Grip6; M Carrasco7; J Foersch8; K Karlsdotter9;M Tuovinen10; R Klement11;MHKyaw12; L Niskanen |
| Affiliations(s): Karolinska Institutet,Department of Clinical Science and Education, Södersjukhuset, Solna, Sweden;2Tel Aviv University, Maccabi Research and Innovation Center, Tel Aviv, Israel;3University of Valencia, Department of Cardiology, Hospital Clínico Universitariode Valencia, INCLIVA, CIBER Cardiovascular, Valencia, Spain;4University of Ulm,Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm, Germany;5Trial FormSupport, Real-World Evidence, Barcelona, Spain;6Swedish Institute for HealthEconomics Quantify Research, Stockholm, Sweden;7Boehringer Ingelheim EspañaS.A., Barcelona, Spain;8Boehringer Ingelheim Pharma GmbH & Co. Kg, HP CountryMedical Affairs, Ingelheim Am Rhein, Germany;9Boehringer Ingelheim AB, Stock-holm, Sweden;10Boehringer Ingelheim KY, Secondment Boehringer Ingelheim UKHEOR Team, Helsinki, Finland;11IQVIA, Global Database Studies, Tartu, Estonia;12Boehringer Ingelheim Pharmaceutical Inc., Connecticut, United States of America;13University of Eastern Finland, Kuopio, Finland; |
Publication(s): European Journal of Heart Failure (2021)23(Suppl. S2) 2–322doi:10.1002/ejhf.2297
|
| Document Type(s): Abstract, Article, |
| Countries: Finland, Germany, Israel, Spain, Sweden, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Diabetes,
2021 |
|
L:
A: |
English
Database Study, Meta analysis, Methodology, Population Based Study, |
|
|
| |
| |
| Burden of pulmonary arterial hypertension in England: retrospective HES database analysis
|
| Author(s): Fernando Exposto 1, Ruben Hermans 2, Åsa Nordgren 2, Luke Taylor 2, Sanam Sikander Rehman 2, Robert Ogley 2, Evan Davies 3, Amina Yesufu-Udechuku 4, Amélie Beaudet |
| Affiliations(s): IQVIA, 210 Pentonville Road, London, N1 9JY, UK.
2IQVIA, London, UK.
3Actelion Pharmaceuticals Ltd, Allschwil, Basel-Landschaft, Switzerland.
4Actelion Pharmaceuticals UK Ltd, High Wycombe, UK. |
Publication(s): Ther Adv Respir Dis. 2021 Jan-Dec; 15: 1753466621995040.
Published online 2021 Feb 23. doi: 10.1177/1753466621995040
|
| Document Type(s): Article, |
| Countries: Switzerland, UK, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Respiratory disease,
2021 |
|
L:
A: |
English
Burden of illness, |
|
|
| |
| |
| Use of Low Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitors (PCSK9i) Initiation |
| Author(s): Rymer JA, Mues KE, Monda KL, Bratton EW, Wirtz HS, Okerson T, Overman RA, Brookhart MA, Muntner P, Wang TY |
| Affiliations(s): From the Duke Clinical Research InstituteDurham NC (J.A.R., T.Y.W.); Center for Observational ResearchAmgen IncThousand Oaks CA (K.E.M., K.L.M., H.S.W., T.O.); IQVIA, Realâ€World Evidence SolutionsDurham NC (E.W.B.); NoviSci, IncDurham NC (R.A.O., M.A.B.); University of North Carolina at Chapel HillChapel Hill NC (M.A.B.); Department of EpidemiologyUniversity of Alabama at BirminghamAL (P.M.). |
Publication(s): Originally published24 Apr 2020https://doi.org/10.1161/JAHA.119.014347Journal of the American Heart Association. ;0:e014347
|
| Document Type(s): Article, |
| Countries: USA, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Medication compliance,
2020 |
|
L:
A: |
English
Epidemiological study, |
|
|
| |
| |
| Concomitant use of drugs known to cause interactions with oral antiplatelets—polypharmacy in acute coronary syndrome outpatients in Finland |
| Author(s): Tuire Prami, Houssem Khanfir, Pål Hasvold, Eeva Reissell, Juhani Airaksinen, Ville Kytö |
| Affiliations(s): Ville Kytö: Heart Center, Turku University Hospital |
Publication(s): European Journal of Clinical Pharmacology (2020) 76:257–265
|
| Document Type(s): Article, |
| Countries: Finland, |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease,
2020 |
|
L:
A: |
English
Population Based Study, Retrospective database analysis, |
|
|
| |
| |
| Évaluation de la population à risque d’hyperkaliémie |
| Author(s): Gilles Berrut1
Anne-Sophie Boureau1
Laure de Decker1
Olivier Hanon2 |
| Affiliations(s): 1 Pôle hospitalo-universitaire
de gérontologie clinique,
CHU Nantes, France
2 Hôpitaux universitaires Paris Centre,
Service de gériatrie, Hôpital Broca,
Université Paris-Descartes, Paris, France |
Publication(s): 10.1684/pnv.2020.0873
|
| Document Type(s): Article, |
| Countries: |
| Click here for the abstract |
C:
Y: |
Cardiovascular disease, Hematology,
2020 |
|
L:
A: |
French
Retrospective database analysis, |
|
|
| |
| |
 2 of 54 
|
|
